VistaGen Therapeutics (VSTA) Strategic Collaborators

VistaGen, a California-based developer of advanced stem cell technologies to create superior drug testing options for pharmaceutical companies, considers strategic collaborators as a cornerstone of its corporate development strategy. To this end, VistaGen has selected a variety of institutional collaborators, providing the company with flexible access to complementary world-class expertise and innovation at a lower cost than developing and maintaining such resources internally.
 
• University Health Network (UHN) – McEwen Centre for Regenerative Medicine
 The UHN in Ontario, Canada, consists of Toronto General Hospital, Toronto Western Hospital, and Princess Margaret Hospital. In addition to patient care, it has become an international source for discovery and education, and offers the largest hospital-based research program in Canada. It conducts major research in transplantation, cardiology, neurosciences, oncology, surgical innovation, infectious diseases, and genomic medicine.
 
• California Institute for Regenerative Medicine (CIRM)
 CIRM has awarded VistaGen nearly $1 million in grant funding for stem cell research and development related to liver cells and the company’s LiverSafe 3DTM product. The associated research and development work is focused on the improvement of techniques and the production of engineered human ES Cell lines leading to superior drug testing.
 
• United States National Institutes of Health (NIH)
 The NIH has awarded VistaGen a total of $11.3 million (since 1998) in non-dilutive R&D grants, including $2.3 million for research in support of the company’s Human Clinical Trials in a Test TubeTM platform.
 
• Cato Research Ltd.
 Cato Research is a global contract R&D organization, dedicated to helping a network of biotechnology and pharmaceutical companies navigate the complex regulatory approval process for new drugs.
 
• Synterys
 Synterys is VistaGen’s chosen medicinal chemistry partner for drug rescue programs. Their scientists help VistaGen drive its drug rescue program forward efficiently and cost effectively.
 
• Duke University
 Duke University is one of the country’s premier academic research institutions, and offers a complementary expertise in cardiac stem cell technology, electrophysiology, and tissue engineering.
 
• Preclinical Services
 VistaGen also intends to work with contract preclinical service providers to conduct candidate selection and IND-enabling preclinical studies with the drug rescue variants it identifies.
 
For additional information, visit the company’s website at www.VistaGen.com

Please see disclaimer on the MissionIR website: http://www.missionir.com/disclaimer